Gilead Submits NDA For Ambrisentan For PAH

Company has requested a priority review, but anticipates receiving a standard 10-month review, pushing the user fee date to Oct. 18.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet